Severe ocular complications of SJS/TEN and associations among pre-onset, acute, and chronic factors: a report from the international ophthalmology collaborative group.
Stevens-Johnson syndrome (SJS)
cold medicine
common cold symptoms
international research collaboration
ocular sequelae
onychopathy
severe ocular complications (SOC)
toxic epidermal necrolysis (TEN)
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
03
2023
accepted:
04
05
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
We formed an international research collaboration that included Japan, South Korea, Brazil, Thailand, Taiwan, the UK, and the US (682 patients from 13 hospitals between 2005 and 2020), to better evaluate the role of race, ethnicity, and other risk factors in the pathophysiology of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Ophthalmologists often see SJS/TEN patients with severe ocular complications (SOC; frequency 50% SJS/TEN patients) when the patients are referred to them in the chronic stage after the acute stage has passed. Global data were collected using a Clinical Report Form, capturing pre-onset factors, as well as acute and chronic ocular findings. Key conclusions of this retrospective observational cohort study were as follows: (1) Ingestion of cold medications [acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs)] was significantly and positively correlated with trichiasis, symblepharon, and/or conjunctivalization of the cornea in the chronic stage; (2) common cold symptoms prior to onset of SJS/TEN were significantly and positively correlated with acute conjunctivitis and ocular surface erosions in the acute stage and with trichiasis and symblepharon and/or conjunctivalization of the cornea in the chronic stage; (3) patients with SJS/TEN who presented with SOC tended to be female; (4) patients less than 30 years of age are more likely to develop SOC in the acute and chronic stages of SJS/TEN; (5) patients with acute severe conjunctivitis with ocular surface erosion and pseudomembrane formation in the acute stage are more likely to develop ocular sequelae in the chronic stage; and (6) onychopathy in the acute stage was positively correlated with ocular sequelae in the chronic stage. Our findings show that the ingestion of cold medications, common cold symptoms prior to the onset of SJS/TEN, and a young age might strongly contribute to developing the SOC of SJS/TEN.
Identifiants
pubmed: 37425307
doi: 10.3389/fmed.2023.1189140
pmc: PMC10325566
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1189140Informations de copyright
Copyright © 2023 Ueta, Inoue, Nakata, Sotozono, Kim, Wakamatsu, Jongkhajornpong, Saeed, Rauz, Ma, Yoon, Puangsricharern, Bouchard, Ahmad, Seo, Joo, Gomes, Chodosh, Kinoshita and Teramukai.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
Front Med (Lausanne). 2021 Nov 17;8:651247
pubmed: 34869401
Hum Mol Genet. 2011 Mar 1;20(5):1034-41
pubmed: 21149285
Br J Ophthalmol. 2018 Sep;102(9):1303-1307
pubmed: 29706602
Sci Rep. 2014 Apr 30;4:4862
pubmed: 24781922
Pharmacogenomics. 2008 Nov;9(11):1617-22
pubmed: 19018717
Pharmacogenet Genomics. 2008 Feb;18(2):99-107
pubmed: 18192896
Am J Ophthalmol. 2020 Nov;219:357-365
pubmed: 32681905
Ophthalmology. 2011 May;118(5):908-14
pubmed: 21440941
JAMA Ophthalmol. 2017 Apr 1;135(4):355-360
pubmed: 28278336
Clin Transl Allergy. 2019 Nov 22;9:61
pubmed: 31768251
Ocul Surf. 2016 Apr;14(2):168-88
pubmed: 26882981
Ther Adv Chronic Dis. 2020 Apr 28;11:2040622319894469
pubmed: 32523661
Am J Ophthalmol. 2018 May;189:17-28
pubmed: 29421293
N Engl J Med. 2011 Mar 24;364(12):1134-43
pubmed: 21428769
Ophthalmology. 2009 Apr;116(4):685-90
pubmed: 19243825
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9
pubmed: 15743917
Cornea. 2016 Feb;35(2):199-204
pubmed: 26655481
J Allergy Clin Immunol. 2010 Dec;126(6):1218-25.e10
pubmed: 20947153
Br J Ophthalmol. 2022 Jun;106(6):884-888
pubmed: 33229345
J Allergy Clin Immunol. 2015 Jun;135(6):1538-45.e17
pubmed: 25672763
Ocul Surf. 2021 Apr;20:173-175
pubmed: 33617977
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES183-DES191
pubmed: 30481825
Epilepsia. 2008 Dec;49(12):2087-91
pubmed: 18637831
Br J Ophthalmol. 2019 Apr;103(4):573-576
pubmed: 30705045
J Allergy Clin Immunol. 2007 Dec;120(6):1457-9
pubmed: 17900677
Br J Ophthalmol. 2022 May;106(5):610-615
pubmed: 33441319
Sci Rep. 2017 Nov 21;7(1):15960
pubmed: 29162886
Am J Ophthalmol. 2015 Aug;160(2):228-237.e2
pubmed: 25979679
Br J Ophthalmol. 2007 Jul;91(7):962-5
pubmed: 17314152
Am J Ophthalmol. 2009 Jun;147(6):1004-11, 1011.e1
pubmed: 19285657
Expert Rev Clin Immunol. 2020 Mar;16(3):285-291
pubmed: 32045311
Pharmacogenomics J. 2013 Feb;13(1):60-9
pubmed: 21912425
Ophthalmology. 2007 Jul;114(7):1294-302
pubmed: 17475335
Pharmacogenomics. 2013 Nov;14(15):1821-31
pubmed: 24236482
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):700-702.e2
pubmed: 28988785
Sci Rep. 2014 Aug 07;4:5981
pubmed: 25099678
Prog Retin Eye Res. 2012 Nov;31(6):551-75
pubmed: 22728145
Sci Rep. 2021 Feb 3;11(1):2928
pubmed: 33536518
Nature. 2004 Apr 1;428(6982):486
pubmed: 15057820